Related Experiment Video
Updated: Aug 14, 2025

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
Published on: May 12, 2013
CDR1as regulates α-synuclein-mediated ischemic brain damage by controlling miR-7 availability
Suresh L Mehta1, Anil K Chokkalla1, Saivenkateshkomal Bathula1
1Department of Neurological Surgery, University of Wisconsin-Madison, Madison, WI 53792, USA.
Abstract:
Transient focal ischemia decreased microRNA-7 (miR-7) levels, leading to derepression of its major target α-synuclein (α-Syn) that promotes secondary brain damage. Circular RNA CDR1as is known to regulate miR-7 abundance and function. Hence, we currently evaluated its functional significance after focal ischemia. Transient middle cerebral artery occlusion (MCAO) in adult mice significantly downregulated both CDR1as and miR-7 levels in the peri-infarct cortex between 3 and 72 h of reperfusion. Interestingly, neither pri-miR-7a nor 7b was altered in the ischemic brain. Intracerebral injection of an AAV9 vector containing a CDR1as gene significantly increased CDR1as levels by 21 days that persisted up to 4 months without inducing any observable toxicity in both sham and MCAO groups. Following transient MCAO, there was a significant increase in miR-7 levels and CDR1as binding to Ago2/miR-7 in the peri-infarct cortex of AAV9-CDR1as cohort compared with AAV9-Control cohort at 1 day of reperfusion. CDR1as overexpression significantly suppressed post-stroke α-Syn protein induction, promoted motor function recovery, decreased infarct size, and curtailed the markers of apoptosis, autophagy mitochondrial fragmentation, and inflammation in the post-stroke brain compared with AAV9-Control-treated cohort. Overall, our findings imply that CDR1as reconstitution is neuroprotective after stroke, probably by protecting miR-7 and preventing α-Syn-mediated neuronal death.
Insights
Circular RNA CDR1as protects the brain after stroke by restoring microRNA-7 levels, reducing alpha-synuclein, and improving motor function recovery. This suggests CDR1as is a potential therapeutic target for stroke treatment.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Transient focal ischemia reduces microRNA-7 (miR-7) levels, leading to increased alpha-synuclein (α-Syn) and secondary brain damage.
- Circular RNA CDR1as regulates miR-7 abundance and function, suggesting a role in ischemic stroke.
Purpose of the Study:
- To investigate the functional significance of CDR1as in focal cerebral ischemia.
- To evaluate the neuroprotective effects of CDR1as reconstitution after stroke.
Main Methods:
- Transient middle cerebral artery occlusion (MCAO) model in adult mice.
- Intracerebral injection of an adeno-associated virus serotype 9 (AAV9) vector carrying the CDR1as gene.
- Measurement of CDR1as, miR-7, and α-Syn levels, infarct size, apoptosis, autophagy, and inflammation markers.
- Assessment of motor function recovery.
Main Results:
- MCAO significantly downregulated CDR1as and miR-7 in the peri-infarct cortex.
- AAV9-mediated CDR1as overexpression increased miR-7 levels and CDR1as binding to Ago2/miR-7.
- CDR1as overexpression suppressed α-Syn induction, reduced infarct size, decreased apoptosis, autophagy, and inflammation, and promoted motor function recovery.
Conclusions:
- CDR1as reconstitution demonstrates significant neuroprotective effects in a mouse model of ischemic stroke.
- CDR1as likely exerts its protective effects by preserving miR-7 and inhibiting α-Syn-mediated neuronal death.
- CDR1as represents a potential therapeutic target for stroke treatment.
More Related Videos
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
Related Concept Videos
Neural Regulation
MicroRNAs